Results 201 to 210 of about 2,777,068 (342)

Sizing and concentration analysis of cfDNA using Biabooster technology: Results from a prospective plasma‐based collection of 77 patients with locally advanced unresectable esophageal cancer

open access: yesInternational Journal of Cancer, EarlyView.
What's New? This study introduces a novel approach for detecting locally advanced esophageal carcinoma using cell‐free DNA (cfDNA) analysis through a highly sensitive fragmentome assay. Unlike traditional sequencing‐based methods that are limited by the absence of specific mutations in esophageal tumors, our method offers an alternative by quantifying ...
Anouchka Modesto   +21 more
wiley   +1 more source

Tolerability of Adjuvant Nivolumab in Esophageal or Gastroesophageal Junction Cancer: A Real‐World Study

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT Adjuvant nivolumab is approved for esophageal or gastroesophageal junction cancer after neoadjuvant chemoradiotherapy and resection. In the CheckMate‐577 trial, Grade 3–5 nivolumab‐related adverse events (AEs) occurred in 5% of patients, with early discontinuation due to toxicity in 9%. However, real‐world data on immunotherapy‐related adverse
Michelle Koops van ’t Jagt   +7 more
wiley   +1 more source

Microbiota profiling in esophageal diseases: Novel insights into molecular staining and clinical outcomes. [PDF]

open access: yesComput Struct Biotechnol J
Barchi A   +12 more
europepmc   +1 more source

Prevalence and age- and sex-related characteristics of esophageal diseases among residents of the Lviv region

open access: diamond
Y. B. Shvydkyi   +3 more
openalex   +1 more source

Home - About - Disclaimer - Privacy